Solriamfetol effective in reducing excessive sleepiness in patients with OSA
Results presented at the recent 2018 Annual Meeting of the American Neurological Association (ANA) in Atlanta show encouraging results with solriamfetol in patients with narcolepsy or obstructive sleep apnea (OSA) in keeping them awake and alert. Solriamfetol is a selective dopamine and norepinephrine reuptake inhibitor.
To continue reading this article
Continue reading your article with a eMediNexus account.